Course: Beyond Statins: Transforming LDL-C Management with Early Combination Therapy and CETP Inhibition
CME Credits: 1.00
Released: 2025-07-17
Evidence has shown that cumulative prior exposure to elevated LDL-C is a critical driver of ASCVD risk in patients. However, many clinicians need more education on how factors like lifetime cholesterol exposure, lipoprotein(a) [Lp(a)] levels, and coronary artery calcium (CAC) scores should influence the aggressiveness of LDL-C-lowering treatment. Join an expert panel of two cardiologists and one primary care provider to discuss CETP inhibitors and how combining novel therapies with current treatments, including statins and ezetimibe, can enhance patient care. Clinicians will be equipped with practical insights on aggressive LDL-C management, patient-centered treatment strategies, and how emerging therapies can address gaps in current practice.
View Full Course